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Abstract
Background Making healthcare treatment decisions is a
complex process involving a broad stakeholder base including
patients, their families, health professionals, clinical practice
guideline developers and funders of healthcare.
Methods This paper presents a review of a methodology
for the development of urological cancer care pathways
(UCAN care pathways), which reXects an appreciation of
this broad stakeholder base. The methods section includes
an overview of the steps in the development of the UCAN
care pathways and engagement with clinical content
experts and patient groups.
Results The development process is outlined, the uses of
the urological cancer care pathways discussed and the
implications for clinical practice highlighted. The full set of
UCAN care pathways is published in this paper. These
include care pathways on localised prostate cancer, locally
advanced prostate cancer, metastatic prostate cancer,
hormone-resistant prostate cancer, localised renal cell can-
cer, advanced renal cell cancer, testicular cancer, penile
cancer, muscle invasive and metastatic bladder cancer and
non-muscle invasive bladder cancer.
Conclusion The process provides a useful framework for
improving urological cancer care through evidence synthesis,
research prioritisation, stakeholder involvement and inter-
national collaboration. Although the focus of this work is
urological cancers, the methodology can be applied to all
aspects of urology and is transferable to other clinical
specialties.
The members of the UCAN Care Pathway Development Group are 
given in the “Appendix”.
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Introduction
Challenges in urological cancer treatment decision-making
In making healthcare decisions regarding treatment, decision
makers are confronted with several fundamental issues. At
the individual level, patients and clinicians are primarily
concerned with the balance between the perceived beneWts
and harms of treatment discussed, whilst for healthcare
systems, policy makers need to know which treatments
should be provided. This societal aspect will be informed
by information on costs, cost-eVectiveness and arguably,
some notion of fairness such as equal access for equal need.
In conditions such as localised prostate cancer for which
multiple management options exist, the situation becomes
even more complex. One approach to facilitate individual
decision-making and decisions regarding treatment provision
is evidence-based medicine [1], in which choices are made
on the basis of the best available evidence obtained from
robust methodology; evidence that is valid, reliable and of
high quality. To be useful, this evidence must be readily
accessible. Systematic reviews are one method of identifying
and synthesising research evidence on a particular subject
[2]. The review process, review Wndings and subsequent
guideline recommendations can also be used to identify
gaps in knowledge about treatment eVects (uncertainties)
and inform future work to address important gaps.
The strengths and limitations of systematic review 
methodology
Reasons for undertaking a systematic review include
resolution of conXicting evidence or clinical uncertain-
ties, explanation of variations in practice, or to conWrm the
appropriateness of current practice. To achieve these out-
comes, a systematic review requires a transparent and repli-
cable synthesis process [3] with eVect estimates obtained
by meta-analysis using appropriate statistical techniques.
Fig. 1 Localised prostate cancer care pathway. Abbreviations: PSA
prostate-speciWc antigen, EBRT electron beam radiotherapy, IMRT
intensity-modulated radiation therapy, HRPC hormone refractory
prostate cancer, LHRH luteinizing hormone-releasing hormone, DXT
deep X-ray therapy, TURP transurethral resection of the prostate,
GVAX granulocyte–macrophage colony-stimulating factor [or GM-CSF]
vaccine, ZD4054 ZibotentanWorld J Urol (2011) 29:291–301 293
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Typically, a systematic review involves a well-formulated
question or questions, comprehensive searches of the major
electronic databases, pre-deWned study eligibility criteria, an
unbiased study selection process and data extraction against a
set of pre-determined outcomes using standard forms. These
data are critically appraised, including rating of the quality of
the evidence and quantitative synthesis with meta-analysis
where appropriate. This transparent and replicable process
diVerentiates systematic from narrative reviews, which are
more prone to bias.
A key limitation of any systematic review is that it
cannot overcome problems inherent in the design, conduct
and reporting of the included primary studies [3–5]. Their
authority can also be undermined by errors in review meth-
odology or reporting leading to variation in conclusions
drawn by separate systematic reviews attempting to answer
the same question. As a consequence, widely accepted
guidelines for the conduct and reporting of primary studies
and systematic reviews, such as CONSORT, Cochrane
Handbook and PRISMA, [6–8] have been established.
DeWning the question
DeWning the review question for a systematic review is the
Wrst and most important stage of the process as this provides
the direction for all subsequent stages [9]. Paradoxically,
while methodology has advanced for the actual process of a
systematic review, there has been little work done to estab-
lish the best way of identifying areas of clinical uncertainty
and prioritising a list of questions that maintains relevance
for all interested groups. One approach is to perform a
scoping study [10]; this involves an initial literature search
to assess whether a full systematic review is both feasible,
that is there are suYcient primary studies available for syn-
thesis, and relevant, that is there is no existing equivalent
review document. Another approach is evidence mapping
[11], which was used by the Global Evidence Mapping
Initiative in Australia [12]. Here, the number and quality of
relevant studies retrieved from literature searches and their
summary outcomes are tabulated for each condition or
treatment of interest. A potential drawback of this approach
is that it does not map the entirety of the research that could
be conducted within a given clinical subject area or indeed
the importance of any gaps within the evidence.
The urological cancer care pathways (UCAN care path-
ways from here on) being developed by our group are an
attempt to address these issues. In September 2004, we
facilitated plenary discussions involving urological clini-
cians, patients and their partners including expertise and
experience of the Wve main cancers: kidney, bladder, prostate,
testis and penis. The purpose was to better understand the
needs of individuals with urological cancer in the context of
Fig. 2 Locally advanced prostate cancer care pathway. For abbreviations, refer Fig. 1294 World J Urol (2011) 29:291–301
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their cultural setting and health system. The principal
messages from patients and their families were that the fol-
lowing improvements are needed: (1) Better and more
accessible information backed up by evidence, which could
help them make decisions about their care, (2) Better care
of for those that suVer unwanted eVects of cancer treatment,
and (3) Better support throughout their journey of care both
in the clinical setting and at home. In response, a Scottish
Charity (UCAN) committed funding of £2.6 million to
address these gaps in urological cancer care focussed on
people living in north-east Scotland but also reXecting an
international perspective. Discussion with the research
group on how to address the Wrst principal message, the
requirement for better and more accessible evidenced-
based information for patients led to the development
methodology to formulate UCAN care pathways, which we
discuss in the present paper.
Our main objective is to map all plausible treatment
options for each of the Wve urological cancers to allow
collection of an appropriate range of existing and new
systematic evidence reviews of eVectiveness and cost-
eVectiveness of alternative treatment options including the
magnitude of risk of short- and long-term adverse eVects. We
will also engage key clinical experts and patients to prioritise
unanswered questions and identify signiWcant evidence gaps
in the evidence to direct future research priorities. The ulti-
mate aim of the UCAN care pathways is to build an evidence
base for the major urological cancers and develop a frame-
work to inform future systematic reviews, clinical practice
guidelines, care algorithms, integrated care pathways and
research priorities [13]. We will also work to establish a
framework for wider engagement of clinicians, patients,
researchers, healthcare policy makers and healthcare funders
in priority setting within this clinical specialty and inform the
development of a set of core outcomes for both research and
clinical practices. The strength of the UCAN care pathways
will be to harness and rationalise all our eVorts to answering
the key questions for universal beneWt.
Development of urological cancer care pathways
What are care pathways?
A care pathway is a tool constructed with multidisciplinary
input and used by healthcare professionals and/or researchers
to map a patient’s journey in terms of which treatments
should be given, by whom, when, and to what outcome
Fig. 3 Metastatic prostate cancer care pathway. For abbreviations, refer Fig. 1World J Urol (2011) 29:291–301 295
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Fig. 4 Hormone-resistant prostate cancer care pathway. For abbreviations, refer Fig. 1
Fig. 5 Localised renal cell cancer care pathway. Abbreviations: HIFU high-intensity focussed ultrasound, CT computed tomography, IFA inter-
feron-alpha, IL2 interleukin 2, 5FU 5 Fluorouracil296 World J Urol (2011) 29:291–301
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[13–16]. This broad characterisation includes many diVerent
terminologies including care proWle, care protocol, critical
care pathway, care map, integrated care pathway, and
diVerent uses dependent on the context, user and the stage
in the research process at which it is considered. Systematic
reviewers, for example, may use a care pathway to identify
all plausible treatment options for a particular patient group
with a view to identifying gaps in current knowledge,
thereby informing possible review questions. Policy makers
may use a care pathway to establish a standardised treat-
ment algorithm for a speciWc clinical problem in clinical
practice that can then be implemented in a particular health-
care organisation [13, 17].
These examples can be seen as occupying two ends of a
process: driving the research agenda on the one hand and
providing a clinical useable output on the other. We see the
UCAN care pathways more as being drivers of the research
agenda but also providing structure for guideline developers.
They are designed to inform the scope, search strategy,
development and prioritisation of focussed clinical
questions for relevant systematic reviews. They lend them-
selves well to informing development (including scope) of
clinical practice guidelines rather than informing actual
practice as is the purpose of clinical practice guidelines.
They provide a framework for systematic review teams and
guidelines panel members to identify and prioritise topic
areas, to highlight areas where guidance is currently lacking
or the evidence is unclear and to reduce redundancy and
resource wasting.
Methodology
Steps in the development of the UCAN care pathways
1. DeWnition of the aim of an individual UCAN care path-
way. For example, what are the treatment options for
localised prostate cancer? This will require a structured
list of options and the eligibility characteristics to enter
the pathway.
2. Establishment of an advisory group. This should
include both clinical and methodological experts drawn
from national and international professional bodies,
together with representation from patient groups as lay
experts and those who have experienced the disease.
The purpose of the advisory group is to provide a range
of user perspectives necessary to inform the develop-
ment of the pathway.
3. Draughting of all plausible treatment options from the
point of diagnosis moving forward to the end of treat-
ment, follow-up and death in the form of a Xow chart to
producing a comprehensive but concise one-page
summary.
Fig. 6 Advanced renal cell cancer care pathway. For abbreviations, refer Fig. 5World J Urol (2011) 29:291–301 297
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4. Iterative development of the pathway by consensus
clearly describing key areas of uncertainty to create a
Wnal version for dissemination (Figs 1, 2, 3, 4, 5, 6, 7,
8, 9, 10).
Engagement with clinical content experts and patient 
groups
The reasons for engaging with content experts are threefold.
First, to ensure that the UCAN care pathways are compre-
hensive and reXect contemporary clinical practice within the
pre-deWned societal location. Second, to achieve engagement
with the process and to give ownership of the UCAN care
pathways, the systematic reviews and any subsequent clinical
practice guidelines driven by the systematic reviews to key
Wgures (opinion formers) within the discipline. This is impor-
tant to facilitate any required behaviour change and the adop-
tion of evidence-based practice across the discipline. Third, to
develop an international collaboration to advance the practice
of evidence-based medicine within urology. Patient involve-
ment is also a necessary step in identifying appropriate
patient-reported outcomes, understanding which approaches
to delivering care and which outcomes are most important to
patients, facilitating shared decision-making and increasing
patient satisfaction.
Use of urological cancer care pathways
Standardisation of terminology (treatment options 
and deWnitions)
Our methodology gives a clear opportunity to gain clear
consensus regarding deWnitions of treatment options. This
precision in terminology is vital to ensure that the conduct
and reporting of research, the systematic review process
Fig. 7 Testicular cancer care pathway. Abbreviations: AFP alpha-
fetoprotein, bhCG beta-human chorionic gonadotropin, BEP bleomycin/
etoposide/cisplatin,  C/A/P chest/abdomen/pelvis, CBOP carboplatin,
bleomycin, vincristine, and cisplatin, CT computed tomography, EP
etoposide/cisplatin,  FSH Follicle-stimulating hormone, HIV human
immunodeWciency virus, HBV hepatitis B virus, HCV hepatitis C virus,
i-s inguinoscrotal,  LDH lactate dehydrogenase, LH luteinizing
hormone, med 1°  medistinal primary, NSGCT non-seminoma germ
cell tumour, PET positron emission tomography, RP 1° retroperitoneal
primary, RPLND retroperitoneal lymph node dissection, RT radiother-
apy, Te21 trial to compare Taxol-BEP vs BEP alone in intermediate
prognosis disease, Te23 trial comparing CBOP BEP combinations in
poor prognosis with BEP, TRISST TRial of imaging and schedule in
seminoma testis, UK United Kingdom, USA United States of America,
Yrs years298 World J Urol (2011) 29:291–301
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and the clinical practice guidelines development process
are relevant to all.
Informing search strategy
The aim of the search strategy for a systematic review is
to maximise both the sensitivity and the speciWcity of the
search results, that is, to retrieve all the relevant articles
and exclude the irrelevant ones. In order to design the
strategy, the question Wrst needs to be translated into
searchable terms using the PICO (Patient, Intervention,
Comparison, Outcome) framework. The UCAN care path-
ways greatly facilitate this step, as all plausible interven-
tions that can be compared are clearly shown for each
patient group at every stage in the disease process. Also,
the format of the pathway allows the reviewer to see
where the search question is focussed in the context of the
entire pathway and to see which interventions and stages
of the disease are being excluded from the search. This is
particularly useful when reWning and reviewing the results
of the search.
Therefore, as the UCAN care pathways succinctly repre-
sent the required detailed and complex information, the
reviewer is readily able to understand the speciWc patient
groups and interventions being reviewed and focus the
search accordingly. Hence, the pathways are a key element
in the design and execution of searches to inform system-
atic reviews for speciWc stages of the pathway. The same
process can be employed in the deWnition of focused clini-
cal questions by clinical practice guideline panels.
Prioritisation (review scope, guideline scope 
and development process)
Systematic reviews can be used to provide more reliable
and precise estimates of relative eVectiveness of competing
treatments and highlight areas where further primary
research is needed. Resources are however always limited,
and therefore, the questions requiring performance of a sys-
tematic review need to be prioritised. There is also a linked
need to prioritise topics for clinical practice guidelines
based on evidence from systematic reviews. Prioritisation
Fig. 8 Penile cancer care pathway. Abbreviations: 5-FU 5 Xuoroura-
cil, CIS carcinoma in situ, DSNB dynamic sentinel node biopsy, FNAC
Fine needle aspiration cytology, MDT multidisciplinary team, SCC
squamous cell carcinoma, USS ultrasound scanningWorld J Urol (2011) 29:291–301 299
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should be a process that is systematic and transparent and
that includes consultation with key experts [18].
The UCAN care pathways inform the prioritisation
process by providing a comprehensive framework for
discussion that is applicable to multiple settings both
nationally and internationally. They also inform the prioriti-
sation process by highlighting where in the process of care
the uncertainty is and the magnitude of the problem in
terms of the number of people aVected and its consequences.
As such, they provide a concise summary of the various
treatment options and inform the scope of systematic
reviews and clinical practice guidelines. The UCAN care
pathway model also ensures that the systematic review
activity is Wrmly embedded in the context of the overall
management of patients.
Economic evaluation and care pathways
Economic evaluation involves the comparative analysis of
alternative interventions in terms of beneWts such as
improvement in health, the value of those improvements to
individual patients and costs [19]. An economic evaluation
has to be based upon a care pathway, as an understanding is
needed of what the sequence of events is from initiation of
the treatment under study. The UCAN care pathways can
be used to identify events that will inXuence a patient’s
well-being and events that use or save resources. Once
these events have been established, they can then be mea-
sured and valued [20].
Estimates of beneWts and costs can be based on data
from randomised controlled trials or from a mathematical
model. The models can be constructed using decision ana-
lytic methods to provide a mathematical representation of a
UCAN care pathway. A model is a further level of evidence
synthesis as it may incorporate the results from a number of
systematic reviews.
In addition to information on cost-eVectiveness, an
economic model can show who stands to beneWt most from
use of a particular healthcare intervention and who is most
likely to bear the cost. These analyses can inform judge-
ments about equity of provision. Economic models can also
be used to highlight areas for further research either by
Fig. 9 Muscle invasive metastatic bladder cancer care pathway.
Abbreviations: BCG bacillus calmette-guérin, CIS carcinoma in situ,
CXR chest X-ray, INF interferon-alpha, IVU intravenous urogram,
LUTS lower urinary tract symptoms, LND lymph node dissection,
MIBC muscle invasive bladder cancer, NMIBC non-muscle invasive
bladder cancer, Prostatic TCC transitional cell carcinoma of the pros-
tate, TB tuberculosis300 World J Urol (2011) 29:291–301
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showing precisely what evidence is missing or more
formally by quantifying the value of further research in
terms of balancing the cost of gaining the new evidence
against the subsequent beneWts that are likely to accrue by
calculation of value of information [21].
Conclusions
We believe that the UCAN care pathways provide a crucial
framework for improving urological cancer care through
evidence synthesis, research prioritisation, stakeholder
involvement and international collaboration. The process of
developing these pathways is an important vehicle for inXu-
encing the discipline of urology by facilitating engagement
with the principles of evidence-based medicine through
international collaboration. They also hold the promise of
advancing the goal of standardising terminology within
urology and improving communication between healthcare
professionals, researchers, patients, policy makers and
funders, in diVerent geographical locations. Finally, they
inform the development and conduct of systematic reviews,
the development of clinical practice guidelines and eco-
nomic evaluation of interventions within urology.
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